Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

Congress and Administration Take Aggressive Action to Address COVID-19 Pandemic but Providers Continue to Struggle

Congress has passed four pieces of legislation and the Centers for Medicare & Medicaid Services…

read more

USP General Chapter <797> News. Media Fill Test Kit

Implementation of the new USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations is still…

read more

HHS Attestation Update

As AMA reported in the AMA Advocacy Update of May 22, HHS announced that providers need to…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

07/15/20: Call for Scientific Papers
Learn more

09/11/20: Membership Application Deadline to be voted in at the 2020 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2020 Annual Meeting Learn more

12/01/20: Research Grant Cycle
Learn more

04/01/21: Fellow Exam Application Deadline
Learn more

06/01/21: Research Grant Cycle
Learn more

06/26/21: Membership Application Deadline to be eligible for AAOA Member rate for the 2021 Basic Course

EDUCATION

On Demand Content!

Register now  for the Core Allergy & Rhinology Concepts: Age of Pandemics and Beyond that is still available on demand! It is a great value for rebooting and training returning or new staff. Core Allergy offers what you need to help refresh or add allergy to your practice — everything from the clinical science to the basics of allergy from a better understanding of testing techniques, vial prep, and dose calculations to other practical implications. Core Rhinology encompassed the highly sought after rhinology content from our former IAR program.  Read More

IFAR

IFAR Impact Factor: 2.454

aaoaf-ifar

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

NOW ON DEMAND!!! Core Allergy and Rhinology Concepts: Age of Pandemics and Beyond
Learn More and Register

Registrants! Use the access button below to Log in and click My Account at the top of the link page to get into the course event page.

2020 AAOA Annual Meeting
October 24-29, 2020
Now Virtual
Learn More and Register

AAOA Clinical Insights
Learn More and Register

USP 797 Online Module
Learn More and Register

2021 Basic Course in Allergy & Immunology
July 15-17 | Seattle, WA

News and Updates

Today in ENT Allergy: AAOA’s Podcast. Episode 2 – A Brief Overview of the Otolarygnic Allergy

In the second episode of the AAOA's NEW podcast series Today in ENT Allergy: AAOA's…

read more

Earn CME Credit in Upcoming Activity Titled: The Role Of Biologics for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

Release Date: August 2020; Expiration Date: August 2021 Nasal polyps impact an estimated 13 million…

read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PATIENT CORNER

Menu

First Drug for Treatment of Peanut Allergy for Children is Approved by FDA

“Peanut allergy affects approximately 1 million children in the U.S. and only 1 out of 5 of these children will outgrow their allergy. Because there is no cure, allergic individuals must strictly avoid exposure to prevent severe and potentially life-threatening reactions,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Even with strict avoidance, inadvertent exposures can and do occur. When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy.”

On January 31st, the U.S. Food and Drug Administration (FDA) approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.

Learn more at www.fda.gov.